Literature DB >> 29096596

Comparison of the Local Tolerability to 5 Long-acting Drug Nanosuspensions with Different Stabilizing Excipients, Following a Single Intramuscular Administration in the Rat.

Ronnie Chamanza1,2, Nicolas Darville1,2, Marjolein van Heerden1, Sandra De Jonghe1.   

Abstract

To investigate the effects of common nanosuspension-stabilizing excipients on the nature and temporal evolution of histopathological changes at intramuscular (i.m.) administration sites, 5 groups of 39 male rats per group received a single injection of 1 of the 5 analogous crystalline drug nanosuspensions containing 200 mg/ml of an antiviral compound with particle sizes of ±200 nm and identical vehicle compositions, except for the type of nanosuspension stabilizer. The investigated stabilizers were poloxamer 338, poloxamer 407, d-α-tocopherol polyethylene glycol 1,000-succinate (TPGS), polysorbate 80, and polysorbate 80 combined with egg phosphatidylglycerol. Histopathology and immunohistochemistry revealed progressive inflammatory changes at the i.m. administration sites and the draining lymph nodes that differed according to the time point of sacrifice and the type of stabilizer. Although the overall time course of inflammatory changes was similar across the groups, differences in the nature, severity, and timing of the inflammatory response were observed between animals injected with poloxamer- or TPGS-containing nanosuspensions and those injected with formulations containing polysorbate 80. A more severe and prolonged active inflammatory phase, the presence of multinucleate giant cells, prolonged macrophage infiltration of the formulation depot, and more persistent histiocytic infiltrates in the lymph nodes were observed in the polysorbate 80-containing nanosuspension groups. Such vehicle-mediated effects could influence the overall tolerability profile of long-acting nanosuspensions.

Entities:  

Keywords:  histopathology; inflammation; long-acting injectable intramuscular administration; nanoparticles; polysorbate 80; stabilizing excipient

Mesh:

Substances:

Year:  2017        PMID: 29096596     DOI: 10.1177/0192623317737295

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  3 in total

1.  Creation of a long-acting nanoformulated dolutegravir.

Authors:  Brady Sillman; Aditya N Bade; Prasanta K Dash; Biju Bhargavan; Ted Kocher; Saumi Mathews; Hang Su; Georgette D Kanmogne; Larisa Y Poluektova; Santhi Gorantla; JoEllyn McMillan; Nagsen Gautam; Yazen Alnouti; Benson Edagwa; Howard E Gendelman
Journal:  Nat Commun       Date:  2018-02-06       Impact factor: 14.919

2.  Design of Montelukast Nanocrystalline Suspension for Parenteral Prolonged Delivery.

Authors:  Jun Soo Park; Min Seop Kim; Min Yeong Joung; Hyun Jin Park; Myoung-Jin Ho; Jun Hyuk Choi; Jae Hee Seo; Woo Heon Song; Young Wook Choi; Sangkil Lee; Yong Seok Choi; Myung Joo Kang
Journal:  Int J Nanomedicine       Date:  2022-08-25

3.  Impact of Excipients and Seeding on the Solid-State Form Transformation of Indomethacin during Liquid Antisolvent Precipitation.

Authors:  Mariana Hugo Silva; Ajay Kumar; Benjamin K Hodnett; Lidia Tajber; René Holm; Sarah P Hudson
Journal:  Cryst Growth Des       Date:  2022-09-09       Impact factor: 4.010

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.